|
|
Volumn 92, Issue 18, 2000, Pages 1462-1464
|
|
New discoveries still abundant in monoclonal antibody research.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMINOGLYCOSIDE;
ANTIINFECTIVE AGENT;
ANTINEOPLASTIC AGENT;
CETUXIMAB;
HYBRID PROTEIN;
IODINE 131 ANTI B1 ANTIBODY;
IODINE-131 ANTI-B1 ANTIBODY;
MONOCLONAL ANTIBODY;
Y2B8 MONOCLONAL ANTIBODY;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
ANIMAL;
APOPTOSIS;
ARTICLE;
B LYMPHOCYTE;
DRUG INDUSTRY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IMMUNOLOGY;
NEOPLASM;
PHASE 3 CLINICAL TRIAL;
UNITED STATES;
AMINOGLYCOSIDES;
ANIMALS;
ANTI-BACTERIAL AGENTS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
APOPTOSIS;
B-LYMPHOCYTES;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS, PHASE III;
DRUG INDUSTRY;
HUMANS;
NEOPLASMS;
RADIOTHERAPY, ADJUVANT;
RECOMBINANT FUSION PROTEINS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
MLCS;
MLOWN;
|
|
EID: 0034692326
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/92.18.1462 Document Type: Article |
|
Times cited : (3)
|
|
References (0)
|
